Your browser doesn't support javascript.
loading
Characterizing Opioid Prescribing Trends of Medical Oncologists From 2013 to 2019: Analysis From the Centers for Medicare & Medicaid Services Medicare Part D Prescribers Database.
Korst, Mark R; Santos Teles, Marco; Choudhry, Hassaam S; Santitoro, Joseph G; Garcia, Daniel J; Schwab, Sophia Marie T; Kra, Joshua A.
Afiliação
  • Korst MR; Rutgers New Jersey Medical School, Newark, NJ.
  • Santos Teles M; Rutgers New Jersey Medical School, Newark, NJ.
  • Choudhry HS; Rutgers New Jersey Medical School, Newark, NJ.
  • Santitoro JG; Rutgers New Jersey Medical School, Newark, NJ.
  • Garcia DJ; Rutgers New Jersey Medical School, Newark, NJ.
  • Schwab SMT; Cornell University, Ithaca, NY.
  • Kra JA; Division of Hematology/Oncology, Rutgers New Jersey Medical School, Rutgers Cancer Institute of New Jersey at University Hospital, Newark, NJ.
JCO Oncol Pract ; 20(2): 268-277, 2024 Feb.
Article em En | MEDLINE | ID: mdl-38061003
ABSTRACT

PURPOSE:

Opioid prescribing trends in medical oncology are poorly defined past 2017, the year after the CDC updated opioid prescription guidelines in noncancer settings. We aim to characterize pain management by medical oncologists by analyzing opioid and gabapentin prescribing trends from 2013 to 2019, identify physician-related factors associated with prescribing patterns, and assess whether CDC guidelines for nononcologic settings changed prescribing patterns.

METHODS:

The Centers for Medicare & Medicaid Services (CMS) Medicare Part D Prescribers-by Provider, CMS Medicare Part D Prescribers-by Provider and Drug, and CMS Medicare Physician National Downloadable files from 2013 to 2019 were merged by National Provider Identification. The database included physicians' sex, years of practice, regions, and practice settings. Multivariable binary logistic regression identified significant predictors of total opioid, long-acting opioid, and gabapentin prescriptions.

RESULTS:

Binary logistic regression modeling revealed no significant difference in mean daily total opioid prescriptions from 2013 to 2017. Daily opioid prescriptions by medical oncologists decreased significantly after 2017 (P < .001). Increased opioid prescribing was associated with physician male sex (P < .001), practicing over 10 years (P < .001), and practice in nonurban areas (P < .001). Opioid prescribing was greatest in the South and Midwest United States (P < .001). The same patterns were observed with total long-acting opioid prescriptions, whereas gabapentin prescribing increased from 2013 to 2019 (P < .001).

CONCLUSION:

Opioid prescriptions by medical oncologists decreased significantly from 2013 to 2019, but this decrease was most substantial from 2017 to 2019. These results may imply that the 2016 CDC guidelines influenced medical oncologists, particularly more junior physicians in urban settings, to manage chronic cancer pain with alternative therapies.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Medicare Part D / Oncologistas Limite: Aged / Humans / Male País/Região como assunto: America do norte Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Medicare Part D / Oncologistas Limite: Aged / Humans / Male País/Região como assunto: America do norte Idioma: En Ano de publicação: 2024 Tipo de documento: Article